NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Receives Consensus Recommendation of “Moderate Buy” from Analysts

NeuroOne Medical Technologies Corporation (NASDAQ:NMTC) has been assigned a consensus rating of “Moderate Buy” from the five brokerages that are presently covering the firm, Marketbeat reports. One research analyst has rated the stock with a sell rating, three have assigned a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have issued a report on the stock in the last year is $1.9833.

Several equities analysts have recently weighed in on the stock. Zacks Research raised shares of NeuroOne Medical Technologies from a “hold” rating to a “strong-buy” rating in a research report on Monday, January 5th. Wall Street Zen upgraded NeuroOne Medical Technologies to a “sell” rating in a report on Saturday, February 21st. Finally, JonesTrading assumed coverage on NeuroOne Medical Technologies in a research report on Monday. They issued a “buy” rating and a $1.50 target price on the stock.

Institutional Trading of NeuroOne Medical Technologies

Large investors have recently modified their holdings of the stock. Goldman Sachs Group Inc. acquired a new position in NeuroOne Medical Technologies during the first quarter valued at approximately $84,000. Warberg Asset Management LLC acquired a new stake in shares of NeuroOne Medical Technologies in the 2nd quarter valued at $27,000. XTX Topco Ltd bought a new position in shares of NeuroOne Medical Technologies in the 2nd quarter valued at $51,000. Sio Capital Management LLC acquired a new position in shares of NeuroOne Medical Technologies during the 2nd quarter worth $2,390,000. Finally, Focus Financial Network Inc. acquired a new position in shares of NeuroOne Medical Technologies during the 3rd quarter worth $31,000. 16.07% of the stock is owned by institutional investors and hedge funds.

NeuroOne Medical Technologies Stock Performance

NASDAQ NMTC traded down $0.02 during trading hours on Monday, hitting $0.66. 76,662 shares of the company traded hands, compared to its average volume of 286,860. The business’s 50-day moving average is $0.81 and its 200-day moving average is $0.80. The stock has a market capitalization of $33.09 million, a price-to-earnings ratio of -3.86 and a beta of 0.71. NeuroOne Medical Technologies has a twelve month low of $0.40 and a twelve month high of $1.16.

NeuroOne Medical Technologies (NASDAQ:NMTC) last released its earnings results on Tuesday, February 17th. The company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. NeuroOne Medical Technologies had a negative net margin of 78.34% and a negative return on equity of 119.92%. The business had revenue of $2.89 million during the quarter, compared to analysts’ expectations of $2.47 million.

NeuroOne Medical Technologies Company Profile

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.